Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: A national observational cohort study

The Lancet Infectious Diseases

Volumn 11, Issue 7, 2011, Pages 516-524

  Zhang, Fujie ^a,b   Dou, Zhihui ^a   Ma, Ye ^a   Zhang, Yao ^a   Zhao, Yan ^a   Zhao, Decai ^a   Zhou, Shuntai ^a   Bulterys, Marc ^c   Zhu, Hao ^a,e   Chen, Ray Y ^d  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADOLESCENT; ADULT; ARTICLE; BLOOD DONOR; BLOOD TRANSFUSION; CD4 LYMPHOCYTE COUNT; CHINA; DATA BASE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RISK FACTOR; SERODIAGNOSIS; SEXUALLY TRANSMITTED DISEASE; TREATMENT INDICATION; VIRUS TRANSMISSION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHINA; COHORT STUDIES; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 79959311099     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(11)70097-4     Document Type: Article

References (46)

1. Shan J China's HIV positive population to hit 740 000 (accessed Oct 15, 2010). http://www.chinadaily.com.cn/2009-11/24/content_9038385.htm.
2. Zhang F, Haberer JE, Wang Y, et al. The Chinese free antiretroviral treatment program: challenges and responses. AIDS 2007, 21(suppl 8):143-148.
3. Zhang FJ, Pan J, Yu L, Wen Y, Zhao Y Current progress of China's free ART program. Cell Res 2005, 15:877-882.
4. Zhang F, Dou Z, Yu L, et al. The effect of highly active antiretroviral therapy on mortality among HIV-infected former plasma donors in China. Clin Infect Dis 2008, 47:825-833.
5. Zhang F, Dou Z, Ma Y, et al. Five-year outcomes of the China National Free Antiretroviral Treatment Program. Ann Intern Med 2009, 151:241-251.
6. Bulterys M, Vermund SH, Chen RY, Ou CY A public health approach to rapid scale-up of free antiretroviral treatment in China: an ounce of prevention is worth a pound of cure. Chin Med J (Engl) 2009, 122:1352-1355.
7. Ma Y, Zhao D, Yu L, et al. Predictors of virologic failure in HIV-1-infected adults receiving first-line antiretroviral therapy in 8 provinces in China. Clin Infect Dis 2010, 50:264-271.
8. Ma Y, Zhang F, Zhao Y, et al. Cohort profile: the Chinese national free antiretroviral treatment cohort. Int J Epidemiol 2010, 39:973-979.
9. Jiang Y, Qiu M, Zhang G, et al. Quality assurance in the HIV/AIDS laboratory network of China. Int J Epidemiol 2010, 39(suppl 2):72-78.
10. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853-860.
11. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998, 352:1725-1730.
12. Shen J, Yu DB Governmental policies on HIV infection in China. Cell Res 2005, 15:903-907.
13. Wu Z, Sullivan SG, Wang Y, Rotheram-Borus MJ, Detels R Evolution of China's response to HIV/AIDS. Lancet 2007, 369:679-690.
14. Wu Z, Sun X, Sullivan SG, Detels R Public health. HIV testing in China. Science 2006, 312:1475-1476.
15. Metzger DS, Zhang Y Drug treatment as HIV prevention: expanding treatment options. Curr HIV/AIDS Rep 2010, 7:220-225.
16. Report on the Global HIV/AIDS Epidemic 2008. Joint United Nations Programme on HIV/AIDS UNAIDS, (accessed Oct 15, 2010). http://www.unaids.org/en/dataanalysis/epidemiology/2008reportontheglobalaidsepidemic/.
17. Boerma JT, Stanecki KA, Newell ML, et al. Monitoring the scale-up of antiretroviral therapy programmes: methods to estimate coverage. Bull World Health Organ 2006, 84:145-150.
18. Mahy M, Tassie JM, Ghys PD, et al. Estimation of antiretroviral therapy coverage: methodology and trends. Curr Opin HIV AIDS 2010, 5:97-102.
19. Thai S, Koole O, Un P, et al. Five-year experience with scaling-up access to antiretroviral treatment in an HIV care programme in Cambodia. Trop Med Int Health 2009, 14:1048-1058.
20. Loubiere S, Boyer S, Protopopescu C, et al. Decentralization of HIV care in Cameroon: increased access to antiretroviral treatment and associated persistent barriers. Health Policy 2009, 92:165-173.
21. Bedelu M, Ford N, Hilderbrand K, Reuter H Implementing antiretroviral therapy in rural communities: the Lusikisiki model of decentralized HIV/AIDS care. J Infect Dis 2007, 196(suppl 3):464-468.
22. Fredlund VG, Nash J How far should they walk? Increasing antiretroviral therapy access in a rural community in northern KwaZulu-Natal, South Africa. J Infect Dis 2007, 196(suppl 3):469-473.
23. Adam MA, Johnson LF Estimation of adult antiretroviral treatment coverage in South Africa. S Afr Med J 2009, 99:661-667.
24. Dou Z, Chen RY, Xu J, et al. Changing baseline characteristics among patients in the China National Free Antiretroviral Treatment Program, 2002-2009. Int J Epidemiol 2010, 39(suppl 2):56-64.
25. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001, 286:2568-2577.
26. Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: collaborative analysis of cohorts of HIV-1-infected patients. J Acquir Immune Defic Syndr 2007, 46:607-615. Antiretroviral Therapy Cohort Collaboration.
27. Zwahlen M, Harris R, May M, et al. Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. Int J Epidemiol 2009, 38:1624-1633.
28. Nash D, Katyal M, Brinkhof MW, et al. Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. AIDS 2008, 22:2291-2302.
29. Murphy EL, Collier AC, Kalish LA, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001, 135:17-26.
30. Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 2006, 296:782-793.
31. Severe P, Leger P, Charles M, et al. Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med 2005, 353:2325-2334.
32. Ferradini L, Jeannin A, Pinoges L, et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 2006, 367:1335-1342.
33. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006, 367:817-824.
34. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009, 360:1815-1826.
35. Althoff KN, Gange SJ, Klein MB, et al. Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis 2010, 50:1512-1520.
36. Guidance on provider-initiated HIV testing and counseling in health facilities WHO, (accessed Dec 5, 2009). http://www.who.int/hiv/pub/vct/pitc/en/index.html.
37. Paltiel AD, Weinstein MC, Kimmel AD, et al. Expanded screening for HIV in the United States-an analysis of cost-effectiveness. N Engl J Med 2005, 352:586-595.
38. Shouse RL, Kajese T, Hall HI, Valleroy LA Late HIV testing-34 states, 1996-2005. MMWR 2009, 58:661-665.
39. Dou Z, Chen RY, Wang Z, et al. HIV-infected former plasma donors in rural central China: from infection to survival outcomes, 1985-2008. PLoS One 2010, 5:e13737.
40. Yin W, Hao Y, Sun X, et al. Scaling up the national methadone maintenance treatment program in China: achievements and challenges. Int J Epidemiol 2010, 39:29-37.
41. Wolfe D, Carrieri MP, Shepard D Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet 2010, 376:355-366.
42. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009, 373:48-57.
43. Montaner JS, Lima VD, Barrios R, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 2010, 376:532-539.
44. Das M, Chu PL, Santos GM, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One 2010, 5:e11068.
45. Lima VD, Hogg RS, Montaner JS Expanding HAART treatment to all currently eligible individuals under the 2008 IAS-USA Guidelines in British Columbia, Canada. PLoS ONE 2010, 5:e10991.
46. Initiation of antiretroviral treatment protects uninfected sexual partners from HIV infection (HPTN study 052) HIV Prevention Trials Network, (accessed May 16, 2011). http://www.hptn.org/web%20documents/PressReleases/HPTN052PressReleaseFINAL5_12_118am.pdf.